According to Fosun Pharmaceutical's announcement, the new indications for ruvometinib tablets from Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., the company's holding subsidiary, were approved by the State Drug Administration. The approved indications are for adult patients with neurofibromatosis type I with symptomatic and inoperable plexiform neurofibromatosis. This drug is a MEK1/2 selective inhibitor independently developed by the Group. Three indications have previously been approved for marketing in China, and many other indications are in clinical trials. As of July 2026, the Group has invested a total of about 714 million yuan in research and development of this drug.

According to Fosun Pharmaceutical's announcement, the new indications for ruvometinib tablets from Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., the company's holding subsidiary, were approved by the State Drug Administration. The approved indications are for adult patients with neurofibromatosis type I with symptomatic and inoperable plexiform neurofibromatosis. This drug is a MEK1/2 selective inhibitor independently developed by the Group. Three indications have previously been approved for marketing in China, and many other indications are in clinical trials. As of July 2026, the Group has invested a total of about 714 million yuan in research and development of this drug.